Bone Surgery 


An increasing number of surgical treatments are performed for orthopedic pathologies in pets. Procedures such as arthrodesis or Tibial Tuberosity Advancement (TTA) have become reference treatments in cases of fractures or rupture of the cranial cruciate ligament (CCLD). Bone grafts, synthetic bone substitutes or metallic implants are often associated with these surgeries in order to improve bone repair and fusion but have various limitations in terms of availability, pain and risk of infection. Thanks to its properties, BIOCERA-VET ideally meets the characteristics expected by veterinarians in order to limit pain and the risks of infection and to promote bone repair and consolidation.  


The clinical indications of BIOCERA-VET - BONE SURGERY* - are:  

  • Arthrodesis
  • Fractures
  • Corrective osteotomy
  • TTA (Tibial Tuberosity Advancement)
  • All indications for which bonegrafts are required


More info about BIOCERA-VET

Order here


*currently available for the European market only




Osteosarcoma is a primary tumor of the bone that is the most common cancer in dogs and cats. Amputation of the affected limb is the treatment of choice, but it is not always possible (weakened animals, overweight, having already undergone an amputation, ...). Conservative therapy consisting in the removal of the tumor bone segment while maintaining limb function can be performed. Like amputation, this technique does not prevent cancer development and is often combined with chemotherapy in order to improve the quality of life and prolong the survival of the animal.


BIOCERA-VET* provides an alternative of choice to amputation and to conservative treatment. Indeed, the injection of BIOCERA-VET into the bone cavity is intended to limit the pain, to reduce the risk of pathological fracture by reinforcing the structural strength of the affected bone tissue and improving mechanical support.


*currently available for the European market only




Osteoarthritis is the most common cause of lameness in pets and affects more than 34 million dogs worldwide. Current treatments combine a conservative approach (weight control and physiotherapy), drugs and surgery aimed at reducing pain and inflammation. These treatments may not be very effective or may be associated with significant side-effects or very invasive.


Considering its characteristics and unique mechanism of action (restoration of homeostasis, anti-inflammatory effects and tissue regeneration), VISCO-VET1, veterinary medicinal product under investigation,  will provide an effective and minimally invasive solution without side effects.


Cranial Cruciate Ligament Deficiency


Cranial cruciate ligament deficiency, affecting over 4 million dogs, is currently managed surgically. Deficiency of the cranial cruciate ligament is often a bilateral condition with increased risk of rupture of the contralateral ligament within 12 to 18 months following the initial diagnosis. Currently, no preventive treatment is available to avoid rupture of the contralateral ligament, which will therefore require a second surgical procedure.


By these pro-regenerative and anti-inflammatory properties, VISCO-VET1, a veterinary medicinal product under investigation, will offer an innovative and minimally invasive solution to prevent rupture of the contralateral ligament.


Tendon and ligament injuries


Tendon and ligament injuries (TLI) are a common cause of lameness in dogs. These lesions often appear as a result of a trauma or following micro-lesions caused by chronic stress. Currently, conservative treatments such as reduction of physical activity, use of anti-inflammatory drugs or intra-articular administration of steroids are encouraged. However, these treatments may lack effectiveness and are sometimes associated with side-effects. A surgical treatment is an alternative but is the source of frequent post-operative complications.


VISCO-VET1 combines local regenerative and anti-inflammatory effects promoting tissue regeneration essential for wound healing. VISCO-VET1, , a veterinary medicinal product under investigation, will therefore constitute a treatment of choice in this indication.


More info about VISCO-VET


VISCO-VET is an investigational veterinary product currently under clinical assessment for its efficacy and safety in canine osteoarthritis and cranial cruciate ligament deficiency.



Warning : VISCO-VET is a medicinal veterinary product under investigation that did not received yet a market authorization. The product is then not available for sale.

This website uses cookies The website of TheraVet SA uses functional cookies. In case of analysing our traffic or advertising, we also place cookies that share information about your use of our site with our analytics partners, our social media and advertising partners, who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.
Show details Hide details
Allow selection Allow all cookies